Search Results 491-500 of 17710 for SC

  1. A Study To Examine The Long-Term Safety, Tolerability And Effectiveness Of APL-130277 For The Acute Treatment Of "OFF" Episodes In Patients With Parkinson's Disease - Mayo Clinic

    Treatment with any form of s.c. apomorphine within 7 days prior to the initial Screening Visit (SV1). Patients that stopped s.c. apomorphine for any reason ...

  2. Abaloparatide (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Abaloparatide is used to treat osteoporosis, and reduces the risk of having bone and spine fractures, in postmenopausal women with osteoporosis. It also ...

  3. Brett C. Bade, M.D. - Doctors and Medical Staff - Mayo Clinic

    Post Doctoral Fellowship - Pulmonary and Critical Care FellowMedical University of South Carolina. 2013. Resident - Post Doctoral Medical Resident Medical ...

  4. Adalimumab-adbm (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Adalimumab-adbm injection is used to treat the symptoms and prevent the progression of moderate to severe rheumatoid arthritis and ankylosing spondylitis. It is ...

  5. Sports Medicine Research - Meniscus Injury

    Faucett SC, Geisler BP, Chahla J, Krych AJ, Kurweil PR, Garner AM, Liu S, LaPrade RF, Pietzsch JB. Meniscus root repair vs meniscectomy or nonoperative ...

  6. Meet Our Fellows - Child and Adolescent Psychiatry Fellowship (Minnesota) - Mayo Clinic School of Graduate Medical Education

    Riddick Blocker, M.D. (Chief fellow). Hometown: Medical school: College of Medicine, Medical University of South Carolina, Charleston, SC. About me: My name ...

  7. Publications - Katrina S. Pedersen, M.D. - Mayo Clinic

    ... SC, Tan BR, Wise PE, Silviera ML, Smith RK, Suresh R, Byrnes K, Samson PP, Badiyan SN, Henke LE, Mutch MG, Kim H. Circumferential Resection Margin as ...

  8. A Randomized, Double-blind, Placebo-controlled Study To Investigate The Efficacy And Safety Of Depemokimab In Adults With Hypereosinophilic Syndrome (HES) - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness of depemokimab 200 mg subcutaneous (SC) given every 6 months versus placebo in participants with ...

  9. Sleep disorders - Doctors and departments - Mayo Clinic

    Blumenthal, M.D.. Cardiologist. Jacksonville, FL. Kimberly ...

  10. A Study To Evaluate The Safety And Efficacy Of ABT-494 For Induction And Maintenance Therapy In Subjects With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    ... [SC] or intramuscular ... at least one 2-week induction regimen of golimumab (one 200 mg SC dose followed by one 100 mg SC dose at least 2 weeks apart); ...